Biomed Industries, Inc.™ is a clinical stage pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs.
The Company has developed a new family of drugs for the treatment of neurodegenerative diseases as well as diabetes-induced obesity.
Its flagship drug, NA-831, an oral formulation for the treatment and prevention of Alzheimer’s Disease, has shown significant efficacy and safety in a Phase 2 clinical trial. Biomed is also focused on the treatment of Major Depressive Disorder, Rett Syndrome, and other neurodegenerative diseases such as Parkinson's Disease and ALS.
The Company is also targeting a new treatment for diabetes-related obesity which greatly reduces adverse events seen in current weight-loss drugs.
Traneurocin™ or NA-831 provides neuroprotection and catalyzes the regeneration of new neurons. Oral 30 mg per day for patients with early onset of Alzheimer’s Disease. NA-831 is manufactured by NeuroActiva, a subsidiary of Biomed.
Learn more
Biomed Digital is harnessing the power of wearable technology and machine learning to create a digital phenotype that helps clinicians to diagnose early onset of Alzheimer’s disease.
Learn more
Biomed is conducting Phase 3 clinical trials of NA-831 for the treatment and prevention of Alzheimer’s disease. We also plan Phase 2/3 trials of NA-831 in combination with Atazanavir, Remdesivir, and Dexaneurosone and Ivermectin for treating Covid-19
Learn more
Vineurocin (NA-704) is an injectable drug designed to stimulate neurogenesis and reduce muscular spasticity, a candidate for treatment of Alzheimer’s disease and Parkinson’s disease. NA-704 can be administered with the MICROS. NA-704 is in the Phase 1 safety studies.
Learn more
The MICROS is a controlled release infusion system which has been approved for marketing in the US. It is used for intravenous administration of injectable drugs. NA-704 can be administered via the MICROS at home care settings. It is an accurate, safe and cost effective drug delivery system.
Learn more
In addition to Alzheimer's Disease, NA-831 shows promise as a treatment for MDD due to its neuroprotective properties. Results of a Phase 1B study have demonstrated a clean safety profile with no adverse side effects.
Learn more
